IMMUNOGLOBULIN THERAPY. Information for Patients

Size: px
Start display at page:

Download "IMMUNOGLOBULIN THERAPY. Information for Patients"

Transcription

1 IMMUNOGLOBULIN THERAPY Information for Patients

2 2

3 WHAT ARE IMMUNOGLOBULINS? Immunoglobulins (Ig) are antibodies, which are usually found naturally in our blood, saliva, tears and mucus. They defend our bodies by fighting infections. WHAT IS IMMUNOGLOBULIN THERAPY USED FOR? Immunoglobulins are used to treat conditions where there are less of these antibodies than we need or they are missing altogether. Such conditions are known as Primary Immunodeficiency, and include: - - Common Variable Immunodeficiency - IgG Subclass Deficiency - Specific Antibody Deficiency - IgA Antibody Deficiency - X Linked Antibody Deficiency. - Hyper IgM Syndrome (CD40 ligand deficiency) HOW CAN IMMUNOGLOBULIN THERAPY BE GIVEN? In Leicester Ig therapy is given in two main ways 1. Intravenously (IV) into a vein. 2. Subcutaneously (SC) under the skin. The right treatment for you will be discussed with you by the Consultant Clinical Immunologist and the Specialist Nurse in Immunology. HOW DOES IMMUNOGLOBULIN THERAPY WORK? By giving IV or SC Ig the antibodies that are missing from the blood are replaced. This helps the body to fight off or prevent future infections. ARE THERE ANY SIDE EFFECTS OR RISKS WITH THIS TREATMENT? Although side effects or adverse reactions are rare they may still occur. Symptoms may include nausea, chills, chest pain and headaches. 3

4 The immunoglobulin is manufactured from a large amount of blood and goes through different stages of preparation to detect and inactivate viruses such as Hepatitis B, Hepatitis C and HIV. However there is still a small risk that blood borne infections such as Hepatitis, and others which have not yet been discovered, may be transmitted through immunoglobulin. It is important that this small risk is weighed against the benefits of treatment for each patient. HOW LONG WILL I NEED TO HAVE IMMUNOGLOBULIN THERAPY? Because these conditions are caused by an inability of the body to make antibodies to fight disease, the treatment will most likely be continued indefinitely. HOW OFTEN IS IMMUNOGLOBULIN THERAPY GIVEN? Usually Ig therapy is given every 2-3 weeks if given IV or every 1-2 weeks if given SC depending on each patient's requirements. HOW LONG WILL THE INFUSION TAKE? For your first infusion you may only have a test dose of Ig which will be given very slowly and will probably take all day. Depending on the dose IVIg infusions generally take 4-5 hours every 2-3 weeks, and SCIg 1-2 hours every 1-2 weeks. DO I HAVE TO COME TO HOSPITAL FOR THERAPY? Initially your therapy will be hospital based until the Consultant Clinical Immunologist, Specialist Nurse and yourself are satisfied that there are no side effects and that you are responding to therapy (about four to six months). Then if you fulfil certain criteria you may be entered into the Home Therapy Programme. 4

5 For further information please talk to your Specialist Nurse or your Consultant Clinical Immunologist at this hospital. Telephone: Or Contact the Primary Immunodeficiency Association (PiA), who produce a number of very useful leaflets about all aspects of primary Immunodeficiency and can be contacted at:- PiA, Alliance House, 12 Caxton Street, London, SW1H 0QS. Telephone: Facsimile: Website: 5

6 6

7 If you would like this information in another language or format, please contact the Service Equality Manager on Haddaad rabto warqadan oo turjuman oo ku duuban cajalad ama qoraal ah fadlan la xiriir, Maamulaha Adeegga Sinaanta Eĝer bu broşürün (kitapçıĝın) yazılı veya kasetli açıklamasını isterseniz lütfen servis müdürüne telefonundan ulaşabilirsiniz. Written by Janet Harrison and Laura King - Specialist Nurses in Immunology. Department of Immunology University Hospitals of Leicester NHS Trust Leicester Royal infirmary NHS Trust. Written: October 1999 Updated: November 2007 Revision due: November

8 8

Parenteral nutrition (PN) therapy

Parenteral nutrition (PN) therapy Parenteral nutrition (PN) therapy Nutrition Nurse Specialists Information for Patients i University Hospitals of Leicester NHS Trust Introduction This leaflet aims to tell you about your intravenous feed

More information

Heart Murmurs. Neonatal Services. Information for Parents. University Hospitals of Leicester NHS Trust

Heart Murmurs. Neonatal Services. Information for Parents. University Hospitals of Leicester NHS Trust Heart Murmurs Neonatal Services Information for Parents University Hospitals of Leicester NHS Trust 2 Introduction During a routine examination your baby was noted to have a heart murmur. This leaflet

More information

Periocular Skin Cancer and the 2 Stage Surgical Procedure

Periocular Skin Cancer and the 2 Stage Surgical Procedure Periocular Skin Cancer and the 2 Stage Surgical Procedure Leicester Royal Infirmary Ophthalmology Department Information for Patients University Hospitals of Leicester NHS Trust Introduction You have been

More information

Your new plaster cast

Your new plaster cast Your new plaster cast Plaster Room Information for Patients i This booklet aims to help you with your new plaster cast University Hospitals of Leicester NHS Trust Contact numbers Telephone numbers: Plaster

More information

Joint Injection / Aspiration

Joint Injection / Aspiration Joint Injection / Aspiration Department of Radiology Information for Patients i Radiology Leaflet No. 12 University Hospitals of Leicester NHS Trust What is a joint injection? A joint injection is an injection

More information

Having a Lung Biopsy. Department of Radiology. Information for Patients. Radiology Leaflet No. 57. University Hospitals of Leicester.

Having a Lung Biopsy. Department of Radiology. Information for Patients. Radiology Leaflet No. 57. University Hospitals of Leicester. Having a Lung Biopsy Department of Radiology Information for Patients i Radiology Leaflet No. 57 University Hospitals of Leicester NHS Trust Contents Page number 1. Introduction 3 2. Referral and consent

More information

Information for Patients having a CT (Computed Tomography) Scan

Information for Patients having a CT (Computed Tomography) Scan Information for Patients having a CT (Computed Tomography) Scan Department of Radiology Information for Patients i University Hospitals of Leicester NHS Trust Introduction If you are an outpatient please

More information

MRI Scan of the Small Bowel (MRI Enterogram)

MRI Scan of the Small Bowel (MRI Enterogram) MRI Scan of the Small Bowel (MRI Enterogram) Department of Radiology Information for Patients i Radiology Leaflet No. 73 University Hospitals of Leicester NHS Trust Introduction If you are an outpatient

More information

Information for Patients, Relatives and Carers

Information for Patients, Relatives and Carers Delirium Department of Geriatric Medicine Information for Patients, Relatives and Carers This leaflet aims to describe the main symptoms of delirium and highlights those patients that are at high risk

More information

Replacement batteries

Replacement batteries Replacement batteries Hearing Services Department Information for Patients and Relatives i University Hospitals of Leicester NHS Trust Introduction Replacement batteries for your NHS hearing aid are free

More information

Transcatheter Aortic Valve Implantation (TAVI)

Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) Department of Cardiorespiratory Medicine Information for Patients i University Hospitals of Leicester NHS Trust Introduction Transcatheter aortic valve implantation

More information

Large Bowel CT Scan (CT Colonogram)

Large Bowel CT Scan (CT Colonogram) Large Bowel CT Scan (CT Colonogram) Department of Radiology Information for Patients i Radiology Leaflet No. 06 University Hospitals of Leicester NHS Trust Introduction Please read your appointment letter

More information

Manchester Royal Infirmary. Antibody Deficiency. Information For Patients

Manchester Royal Infirmary. Antibody Deficiency. Information For Patients Manchester Royal Infirmary Antibody Deficiency Information For Patients 1 What is Immunodeficiency? Immunodeficiency is the name given to the condition of having a faulty immune system which reduces your

More information

Patient information. Subcutaneous Immunoglobulin Therapy and Home Treatment ( SCIG) Infection and Immunity Directorate PIF 1443 V2

Patient information. Subcutaneous Immunoglobulin Therapy and Home Treatment ( SCIG) Infection and Immunity Directorate PIF 1443 V2 Patient information Subcutaneous Immunoglobulin Therapy and Home Treatment ( SCIG) Infection and Immunity Directorate PIF 1443 V2 An overview of subcutaneous infusion of Immunoglobulin Many patients with

More information

Written by Sara LeBien

Written by Sara LeBien Our Immune System A story for children with primary immunodeficiency diseases Written by Sara LeBien A note from the author The purpose of this book is to help young children who are immune deficient to

More information

Clinical Guidelines for the use of Acupuncture by Physiotherapists

Clinical Guidelines for the use of Acupuncture by Physiotherapists Clinical Guidelines for the use of Acupuncture by Physiotherapists Clinical Support & Imaging CMG Therapy Services 1. Introduction Acupuncture is a form of therapy in which fine needles are inserted into

More information

Understanding PIDD. Primary Immunodeficiency Disease (PIDD)

Understanding PIDD. Primary Immunodeficiency Disease (PIDD) Understanding PIDD Primary Immunodeficiency Disease (PIDD) Understanding PIDD Primary Immunodeficiency Disease (PIDD) What is Primary Immunodeficiency? Primary Immunodeficiency (PIDD or PID) is a disease

More information

Subcutaneous ImmunoglobulinTherapy A New Way of Permanent Treatment in Primary Immunodeficiencies Gaby Strotmann

Subcutaneous ImmunoglobulinTherapy A New Way of Permanent Treatment in Primary Immunodeficiencies Gaby Strotmann Subcutaneous ImmunoglobulinTherapy A New Way of Permanent Treatment in Primary Immunodeficiencies Gaby Strotmann Immunodeficiency Department University Children s Hospital Dr. von Haunersches Kinderspital

More information

2013 National Treatment Survey. Immune Deficiency Foundation

2013 National Treatment Survey. Immune Deficiency Foundation 2013 National Treatment Survey Immune Deficiency Foundation IDF 2013 Treatment Survey Mail-based, pencil & paper survey Over 75 Main questions Survey in the field December 2013-March 2014 IDF mail invitation

More information

Highlights from the IG Living Teleconference, April 5, 2017

Highlights from the IG Living Teleconference, April 5, 2017 Highlights from the IG Living Teleconference, April 5, 2017 Topic: Treating IG Side Effects [This is an edited version of a live teleconference presentation.] Guest Speaker: Mark Riedl, MD, MS, board-certified

More information

1 Ig. Prescribed for PI

1 Ig. Prescribed for PI 1 Ig # Prescribed for PI Hizentra is a prescription medicine used to treat primary immune deficiency (PI) in patients 2 years and older. *Ig=Immunoglobulin Please see full on pages 12 13 and full prescribing

More information

Before you are given Privigen

Before you are given Privigen Normal immunoglobulin (Human) 10% (100 g/l), intravenous injection. Consumer Medicine Information What is in this leaflet This leaflet contains answers to some common questions about. It does not contain

More information

Plasma-derived products Information for patients

Plasma-derived products Information for patients Plasma-derived products Information for patients page 2 You have been given this leaflet as your doctor has advised you that you may require plasma-derived products as a treatment for your bleeding disorder.

More information

Privigen solution for infusion

Privigen solution for infusion Privigen solution for infusion Haematology Patient Information What is is Privigen? Privigen? Privigen belongs in a class of medicines called human normal immunoglobins. Immunoglobulins are also called

More information

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration : Information for the user HEPATECT CP 50 IU/ml solution for infusion Human hepatitis B immunoglobulin for intravenous administration Read all of this leaflet carefully before you start using this medicine

More information

PRIMARY IMMUNODEFICIENCIES CVID MANAGEMENT CVID MANAGEMENT

PRIMARY IMMUNODEFICIENCIES CVID MANAGEMENT CVID MANAGEMENT PRIMARY IMMUNODEFICIENCIES CVID MANAGEMENT CVID MANAGEMENT 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CVID CT IgA IgG IgM IPOPI IVIG SCIG PID Common Variable Immune Deficiency Computerised tomography

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 26 February 2015 EMA/CHMP/BPWP/356950/2013 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on core SmPC for human normal immunoglobulin for subcutaneous

More information

CONSUMER MEDICINE INFORMATION LEAFLET

CONSUMER MEDICINE INFORMATION LEAFLET CONSUMER MEDICINE INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask

More information

IVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010

IVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010 # 1 IVIg USED IN US HOSPITALS SINCE 2010 Your guide to Treatment With Privigen For people with primary immunodeficiency (PI) Proven protection Designed for stability Please see full Important Safety Information

More information

Patient Guide to Immunoglobin Replacement Therapy

Patient Guide to Immunoglobin Replacement Therapy Patient Guide to Immunoglobin Replacement Therapy This booklet is to help you understand a little bit more about what is happening to your health at the moment and what we can do to try and help you stay

More information

X-linked agammaglobulinemia (XLA)

X-linked agammaglobulinemia (XLA) X-linked agammaglobulinemia (XLA) hello@piduk.org 0800 987 898 www.piduk.org About this booklet This booklet provides information on X-linked agammaglobulinemia (XLA). It has been produced by the PID UK

More information

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain

More information

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin Package leaflet: Information for the user Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine

More information

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM 10% [100 mg/ml] is available in single use bottles of 20 ml, 50 ml, 100

More information

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11 EVOGAM Information for patients 11881 Evogam 2014 NZ Patient Brochure Update v11 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have

More information

IgG subclass deficiencies

IgG subclass deficiencies IgG subclass deficiencies hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on IgG subclass deficiencies. It has been produced by the PID UK Medical Advisory

More information

IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL

IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL PRIMARY IMMUNODEFICIENCIES IMMUNOGLOBULINS: ONE SIZE DOESN T FIT ALL IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL 1 PRIMARY IMMUNODEFICIENCIES ABBREVIATIONS IG IPOPI IV PID SC Immunoglobulins

More information

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Mai Thị Bích Ngọc

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Mai Thị Bích Ngọc Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases Mai Thị Bích Ngọc Background Primary immunodeficiency diseases (PIDD): group of over 150 disorders

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Nanogam is intended to be used for the treatment of diseases in patients who are suffering from a shortage of immunoglobulins

More information

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin PACKAGE LEAFLET: INFORMATION FOR THE USER Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.

More information

Understanding Adalimumab

Understanding Adalimumab Understanding Adalimumab Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my treatment? Adalimumab is considered to be

More information

EVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3

EVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3 EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been

More information

HYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist.

HYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist. HYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist. 1 HYPER IgM SYNDROME Also available : COMMON VARIABLE IMMUNODEFICIENCY

More information

Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) Patient information Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura (ITP) This leaflet is for adult patients diagnosed with Immune Thrombocytopenic Purpura also known as Immune Thrombocytopenia

More information

AN ESSENTIAL GUIDE TO dealing with infections

AN ESSENTIAL GUIDE TO dealing with infections LIFE AFTER TRANSPLANT: AN ESSENTIAL GUIDE TO dealing with infections #BMTsupport Essential Guide To Dealing with Infections 1 At Anthony Nolan we take great care to provide up to date and accurate facts

More information

NEMO deficiency syndrome

NEMO deficiency syndrome NEMO NEMO deficiency syndrome hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This leaflet has been produced jointly between PID UK, Great Ormond Street Hospital (GOSH) and the Great North

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Intratect 50 g/l and Intratect 100 g/l are solutions for intravenous infusion (infusion into a vein) for restoration and support

More information

Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency

Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.

More information

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.

Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth. Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names. Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number

More information

Name of Primary Immune Deficiency: Patient/Applicant Name: Parent/Carer Name (if child under 16): Address: Phone: GP: Immunologist:

Name of Primary Immune Deficiency: Patient/Applicant Name: Parent/Carer Name (if child under 16): Address: Phone: GP: Immunologist: Name of Primary Immune Deficiency: Patient/Applicant Name: Parent/Carer Name (if child under 16): Address: Phone: GP: Immunologist: Date: To whom it may concern: A Primary Immune Deficiency (PI) is a genetic

More information

Reports of efficacy and safety studies of primary immunodeficiency

Reports of efficacy and safety studies of primary immunodeficiency 2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency

More information

Immunology and the middle ear Andrew Riordan

Immunology and the middle ear Andrew Riordan Immunology and the middle ear Andrew Riordan The Immune system is NOT there; To baffle medical students To keep Immunologists in a job To encourage experiments on mice The Immune system IS there as a defence

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Intratect 50 g/l solution for infusion. Human normal immunoglobulin (IVIg)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Intratect 50 g/l solution for infusion. Human normal immunoglobulin (IVIg) PACKAGE LEAFLET: INFORMATION FOR THE USER Human normal immunoglobulin (IVIg) Read all of this leaflet ca Read all of this leaflet carefully before you start using this medicine because it contains important

More information

JvD/PL/ PACKAGE LEAFLET

JvD/PL/ PACKAGE LEAFLET JvD/PL/20160721 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER GammaQuin, 160 g/l, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using

More information

1. What Panzyga is and what it is used for

1. What Panzyga is and what it is used for Package leaflet: Information for the user Panzyga, 100 mg/ml solution for infusion Human Normal Immunoglobulin (IVIg) This medicine is subject to additional monitoring. This will allow quick identification

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Hizentra 200 mg/ml solution for subcutaneous injection in pre-filled syringe Human normal immunoglobulin (SCIg = Subcutaneous Immunoglobulin) Read all of this

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital

More information

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using

More information

Return tissue fluid to the bloodstream (fluid balance) Immunity. Transport fats from the digestive tract to the bloodstream

Return tissue fluid to the bloodstream (fluid balance) Immunity. Transport fats from the digestive tract to the bloodstream Lymphatic System L Y M P H A T I C C O M P O N E N T S What is a Lymphatic System? The lymphatic system is a complex system of fluid drainage and transport, immune response, and disease resistance. Fluid

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID Patient s surname/family name Patient s first names Date of birth NHS number (or other identifier)

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00) The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN

More information

Serum Free Light Chain Assay

Serum Free Light Chain Assay Serum Free Light Chain Assay This Infosheet explains what light chains are, what the Serum Free Light Chain Assay is, and why it is used in AL amyloidosis. In AL amyloidosis, abnormal plasma cells in the

More information

Ig Therapy: One Size Does Not Fit All

Ig Therapy: One Size Does Not Fit All Ig Therapy: One Size Does Not Fit All Carla Duff, CPNP, MSN, IgCN Advanced Registered Nurse Practitioner University of South Florida Division of Allergy, Immunology, and Rheumatology 1 Objectives Understand

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Irinotecan- Capecitabine (CAPIRI) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)

More information

A Patient s Guide to Blood Components and Products

A Patient s Guide to Blood Components and Products 2014 A Patient s Guide to Blood Components and Products Contents What is a blood transfusion?... 1 Informed consent... 1 Frequently asked questions about blood transfusions... 2 What can I expect during

More information

Important safety information to minimise the risk of immune-related adverse reactions

Important safety information to minimise the risk of immune-related adverse reactions Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.

More information

Premature Ejaculation

Premature Ejaculation Premature Ejaculation Patient Information Urology Department Author ID: PH Leaflet Number: Urol 014 Version: 4 Name of Leaflet: Premature Ejaculation Date Produced: November 2016 Review Date: November

More information

Treating kidney diseases with rituximab. Information for patients

Treating kidney diseases with rituximab. Information for patients Treating kidney diseases with rituximab Information for patients This leaflet has been written to tell you about rituximab. Your kidney doctor has recommended rituximab as a treatment for your kidney condition,

More information

Human plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml

Human plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml Hepatect CP 1. NAME OF THE MEDICINAL PRODUCT Hepatect CP 50 IU/ml; solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. Human plasma protein 50 mg/ml of which

More information

Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print

Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print Composition 1 ml solution contains: Active ingredients:. plasma proteins

More information

Primary Immunodeficiency

Primary Immunodeficiency Primary Immunodeficiency DiGeorge Syndrome Severe Combined Immunodeficiency SCID X-Linked Agammaglobulinemia Common variable immunodeficiency (CVID) IgA deficiency Hyper- IgM Syndrome Wiskott-Aldrich syndrome

More information

INTRATECT 100 g/l solution for infusion

INTRATECT 100 g/l solution for infusion : Information for the user Intratect 100 g/l, solution for infusion Human normal immunoglobulin (IVIg) Read all of this leaflet carefully before you start using this medicine because it contains important

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient s surname/family name Patient s first names Date of birth Hospital

More information

Treating inflammatory bowel disease

Treating inflammatory bowel disease Treating inflammatory bowel disease Anti TNFa (Infliximab, Adalimumab and Golimumab) Information for patients Gastroenterology This leaflet should not replace the information provided by the drug manufacturer.

More information

Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma.

Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma. Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma. Introduction to Mepact (mifamurtide) Mepact, also known as

More information

Clinical Immunodeficiency. Dr Claire Bethune Consultant Immunologist

Clinical Immunodeficiency. Dr Claire Bethune Consultant Immunologist Clinical Immunodeficiency Dr Claire Bethune Consultant Immunologist Peninsula Specialist Immunodeficiency and Allergy service Eden Unit, Derriford https://www.plymouthhospitals.nhs. uk/eden Or Google Immunology

More information

Tissue Typing for Potential Sibling Stem Cell or Bone Marrow Donors

Tissue Typing for Potential Sibling Stem Cell or Bone Marrow Donors Tissue Typing for Potential Sibling Stem Cell or Bone Marrow Donors Bone Marrow Transplant Unit Information for potential donors i Leaflet number: 541 Version: 5 Produced: October 2018 Review: October

More information

Secondary Immunodeficiency

Secondary Immunodeficiency A guide for patients, their families, friends and healthcare professionals Raising awareness and supporting patients with immunodeficiencies in Australia. Secondary Immunodeficiency Edition 1 Date 15 th

More information

Intravenous anti-cancer treatment

Intravenous anti-cancer treatment Intravenous anti-cancer treatment Information for patients Chemotherapy Name Hospital No Your consultant is Anti-cancer treatment is the term used to describe medicines used to treat cancer including chemotherapy.

More information

Traztuzumab (Herceptin)

Traztuzumab (Herceptin) Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if

More information

Babies receiving a blood transfusion. Information for parents and carers

Babies receiving a blood transfusion. Information for parents and carers Babies receiving a blood transfusion Information for parents and carers SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE Babies receiving a blood transfusion Having a baby in hospital is a difficult time for

More information

University College Hospital

University College Hospital University College Hospital Holistic Needs Assessment (HNA) Information for patients, relatives and carers About this leaflet Having a diagnosis of cancer can affect you and your quality of life in many

More information

Chronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.)

Chronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.) University Teaching Trust Chronic Inflammatory Demyelinating Polyneuropathy (C.I.D.P.) Neurology 0161 206 2323 All Rights Reserved 2016. Document for issue as handout. Information about Chronic Inflammatory

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Rhesonativ 750 IU/ml, solution for injection Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains

More information

DATA SHEET RHESONATIV. NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection

DATA SHEET RHESONATIV. NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection DATA SHEET RHESONATIV NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection DESCRIPTION Rhesonativ contains 625 IU of human anti-d immunoglobulin. Rhesonativ is presented as a solution for

More information

Patient Information Child Health Department

Patient Information Child Health Department Viral Meningitis Patient Information Child Health Department Author ID: MF Leaflet Number: CH 054 Version: 5 Name of Leaflet: Viral Meningitis Date Produced: May 2017 Review Date: May 2019 What is viral

More information

AKI - acute kidney injury

AKI - acute kidney injury AKI - acute kidney injury Ward contact details: All Rights Reserved 2015. Document for issue as handout. My Doctor said I have AKI. What is AKI? AKI is short for acute kidney injury. Some people used to

More information

Patient information leaflet. Royal Surrey County Hospital. NHS Foundation Trust. CT Scanning. Radiology

Patient information leaflet. Royal Surrey County Hospital. NHS Foundation Trust. CT Scanning. Radiology Patient information leaflet Royal Surrey County Hospital NHS Foundation Trust CT Scanning Radiology This leaflet tells you about having a Computerised Tomography (CT) Scan. It explains what is involved

More information

Human Normal Immunoglobulin 20% (20 g per 100 ml), solution for subcutaneous administration.

Human Normal Immunoglobulin 20% (20 g per 100 ml), solution for subcutaneous administration. Human Normal Immunoglobulin 20% (20 g per 100 ml), solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does

More information

HIV/AIDS. Communication and Prevention. Davison Community Schools Grade Six June 2018

HIV/AIDS. Communication and Prevention. Davison Community Schools Grade Six June 2018 HIV/AIDS Communication and Prevention Davison Community Schools Grade Six June 2018 Discussing Sensitive Matters with Your Parents Parents: A child s first and most important teacher Parent s role is to

More information

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth

PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth Page 1 of 6 FORM FERRERI / IELSG PROTOCOL Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS

More information

Burrell Street Sexual Health Services. The Cancer O Need to talk about sexual and intimacy problems?

Burrell Street Sexual Health Services. The Cancer O Need to talk about sexual and intimacy problems? Burrell Street Sexual Health Services The Cancer O Need to talk about sexual and intimacy problems? This leaflet is designed to make you aware of the specialist sexual health counselling service available

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Human Medicines Evaluation Unit London, 27 April 2006 CPMP/BPWG/4027/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN PLASMA DERIVED

More information

University College Hospital. Prostate Artery Embolisation (PAE) Interventional Radiology

University College Hospital. Prostate Artery Embolisation (PAE) Interventional Radiology University College Hospital Prostate Artery Embolisation (PAE) Interventional Radiology If you would like this document in another language or format, or require the services of an interpreter, contact

More information

Upper Respiratory Infections PATIENT INFORMATION LEAFLET. Clinical Governance. Dr David Gilliland FY2

Upper Respiratory Infections PATIENT INFORMATION LEAFLET. Clinical Governance. Dr David Gilliland FY2 Version: 2.0 Upper Respiratory Infections PATIENT INFORMATION LEAFLET Authorised by: (Also state if external document) Clinical Governance Date authorised: June 2017 Next review date: June 2020 Document

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE) Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Bevacizumab + Chemotherapy PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information